medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2016, Number 4

<< Back Next >>

Cir Card Mex 2016; 1 (4)

Mixoma cardiaco: experiencia del Hospital General de México “Dr. Eduardo Liceaga” en diagnóstico y tratamiento oportuno

Tortolero-Sánchez CR, Ramírez-Castañeda S, Mejía-Melgar EM, Flores-Calderón O, Dajer-Fadel WL, Argüero-Sánchez R

Language: Spanish
References: 11
Page: 141-145
PDF size: 385.82 Kb.


ABSTRACT

Objective. To analyse the frecuence of cardiac tumors undergone cardiac surgery in our hospital.
Material and methods. A retrospective analysis on surgical population in Hospital General de México “Dr. Eduardo Liceaga” between 2005 – 2015 was conducted. Twenty six cases diagnosed as cardiac tumor were identified, with review of clinical records and postmortem pathology database, and search PubMed for literature comparison.
Results. Twelve (46%) patients had a diagnosis of atrial myxoma, two (8%) rhabdomyoma, 1 (4%) atrial fibroelastoma, 1 (4%) mediastinal mesothelioma, one (4%) leiomyoma, nine (34%) organized thrombus, and with four cadaveric left atrial myxoma (two recurrences). The most frequent comorbidities were hypertension, dyslipidemia and anemia. Main symptoms were dyspnea fever, and syncope. Independent risk factors were dyslipidemia, hypertension, anemia, EuroSCORE II› 5, and bleeding› 1000cc.
Conclusions. In all patients with suspected diagnosis and echocardiography should be performed not delay the surgery.


REFERENCES

  1. http://www.thoratec.com/medical-professionals/vad-product-information/thoratec-centrimag.aspx ACCESADO el 23 de Junio del 2016.

  2. Zhang J, Gellman B, Koert A, et al. Computational and experimental evaluation of the fuid dynamics and hemocompatibility of the CentriMag bloodpump. Artif Organs 2006;30(3):168-77.

  3. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-fow device inpatients awaiting heart transplantation. N Engl J Med 2007; 357(9): 885-96.

  4. Xie A, Phan K, Yan TD. Durability of continuous-fow left ventricular assistdevices: a systematic review. Ann Cardiothhorac Surg 2014; 3(6): 547-56.

  5. Bawiwala MV, Rao V. Left ventricular device as destination therapy: are wethere yet? Curr Opin Cardiol 2009; 24(2): 184-9.

  6. Patel H, Madanieh R, Kosmas CE, Vatti SK, Vittorio TJ. Complications ofContinuous-Flow Mechanical Circulatory Support Devices. Clin Med Insigths Cardiol 2015; 9(Suppl 2):15-2.

  7. Gilotra NA, Stevens GR. Temporary Mechanical Circulatory Support: A Review of the Options, Indications, and Outcomes. Clin Med Insights Cardiol2014;8(Suppl 1):75-85.

  8. Kirklin JK, Naftel DC, Pagani FD, Kormos RL. Sixth INTERMACS annualreport: a 10,000-patient database. Heart Lung Traspl 2014;33(6):555-64.

  9. McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD,Allen LA.Clinical outcomes after continuous-fow left ventricular assist device: a systematic review. Circ Heart Fail 2014; 7(6): 1003-13.

  10. Rossi M, Serraino GF, Jiritano F, Renzulli A. What is the optimal anticoagulation in patients with a left ventricular assist device? Interact CardioVascThorac Surg 2012; 15(4):733-40.

  11. Gilotra NA, Stevens GR. Temporary Mechanical Circulatory Support: A Review of the Options, Indications, and Outcomes. Clin Med Insights Cardiol2014;8(Suppl 1):75-85.




2020     |     www.medigraphic.com